Raleigh Capital Management Inc. Grows Position in Sanofi $SNY

Raleigh Capital Management Inc. boosted its holdings in shares of Sanofi (NASDAQ:SNY) by 33.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,770 shares of the company’s stock after acquiring an additional 14,212 shares during the period. Sanofi comprises about 0.9% of Raleigh Capital Management Inc.’s portfolio, making the stock its 24th largest position. Raleigh Capital Management Inc.’s holdings in Sanofi were worth $2,735,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Flagship Harbor Advisors LLC purchased a new stake in shares of Sanofi in the 4th quarter worth approximately $25,000. Physician Wealth Advisors Inc. increased its holdings in Sanofi by 180.5% during the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock valued at $28,000 after buying an additional 379 shares during the period. Leonteq Securities AG raised its stake in Sanofi by 95.8% in the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after buying an additional 297 shares in the last quarter. Measured Wealth Private Client Group LLC purchased a new stake in Sanofi during the third quarter worth $29,000. Finally, Palisade Asset Management LLC purchased a new stake in Sanofi during the third quarter worth $30,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Stock Performance

SNY opened at $43.16 on Friday. Sanofi has a 52-week low of $40.89 and a 52-week high of $52.68. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. The company has a market cap of $104.64 billion, a P/E ratio of 12.06, a price-to-earnings-growth ratio of 1.07 and a beta of 0.34. The firm’s 50-day moving average price is $43.68 and its 200-day moving average price is $45.84.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which was paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th were paid a dividend of $2.4225 per share. This represents a yield of 559.0%. The ex-dividend date was Monday, May 4th. This is a positive change from Sanofi’s previous annual dividend of $2.04. Sanofi’s dividend payout ratio (DPR) is currently 49.16%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on SNY shares. BNP Paribas Exane downgraded Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a report on Monday, April 20th. Argus upgraded Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. Citigroup reiterated a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. Finally, Morgan Stanley set a $52.00 target price on shares of Sanofi in a report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $51.00.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.